Memorial Sloan Kettering Cancer Center President and CEO, Selwyn M. Vickers, MD, Elected to the Fellows of the American Association for Cancer Research (AACR) Academy

Selwyn M. Vickers, MD

Memorial Sloan Kettering Cancer Center (MSK) is pleased to announce Selwyn M. Vickers, MD, President and CEO of MSK, is among 30 international scientific leaders elected today to the prestigious Fellows of the American Association for Cancer Research (AACR) Academy class of 2024.

Dr. Vickers has been recognized for his significant contributions to cancer research and joins 18 Fellows of the AACR Academy from MSK previously elected over the program’s 11-year history. Previously elected Fellows from MSK include: the late José Baselga, MD, PhD; Bayard Clarkson, MD; Luis Diaz Jr., MD; the late Jimmie C. Holland, PhD; Maria Jasin, PhD; Thomas J. Kelly, MD, PhD; Scott W. Lowe, PhD; the late Paul A. Marks, MD; Joan Massagué, PhD; Larry Norton, MD; Luis F. Parada, PhD; Nikola P. Pavletich, PhD; Dana Pe’er, PhD; PhD; Neal Rosen, MD, PhD; Alexander Y. Rudensky, PhD; Michel Sadelain, MD, PhD; Charles L. Sawyers, MD; and Craig B. Thompson, MD.

The mission of the AACR Academy is to recognize and honor distinguished scientists whose major scientific contributions have propelled significant innovation and progress against cancer. The AACR Academy leverages the expertise of the global brain trust of its Fellows to prevent and cure all cancers through research, education, communication, collaboration, science policy and advocacy, and funding for cancer research.

“Throughout his impressive career, Dr. Vickers has made significant contributions to the field of pancreatic cancer research, a disease where there is a high unmet need,” said Joan Massague, PhD, Director of Sloan Kettering Institute and Chief Scientific Officer of MSK. “He joins a long list of scientific luminaries from MSK who have been elected by their peers to the prestigious AACR Academy. We congratulate him on this well-deserved recognition.”

Dr. Vickers is being recognized for his work characterizing and targeting pancreas cancer metastasis, development of oncolytic adenoviruses capable of inhibiting pancreas tumor stem cells, and instrumental efforts to develop and evaluate the efficacy of minnelide, a synthetic prodrug of the diterpene triepoxide triptolide, as a pro-apoptotic chemotherapeutic for the treatment of pancreas and hepatocellular carcinoma.

Nick Gardner
Manager, Media Relations
[email protected]